ArticleiScience2026
Immune-metabolic profiling of triple-negative breast cancer during neoadjuvant chemotherapy.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multi-omics study investigated immune and metabolic determinants of neoadjuvant chemotherapy (NAC) response in triple-negative breast cancer. Analyzing samples from 32 patients, responders exhibited systemic and intratumoral expansion of metabolically active, functionally competent immune cells, including effector memory T cells and activated dendritic cells with enhanced oxidative phosphorylation. Non-responders displayed immune exhaustion and metabolic suppression, with enriched terminally differentiated T cells and senescent NK cells. Transcriptomic and spatial analyses revealed that non-responder tumors were dominated by hypoxia, driving fatty acid oxidation and lymphocyte dysfunction. These findings demonstrate that pre-treatment immune-metabolic fitness in T and B cells is strongly associated with chemosensitivity, offering a promising avenue for predictive biomarker development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.